Unique resources for CNS research
Central nervous system (CNS) disorders account for about 35 percent of the total disease burden in the world’s seven largest pharmaceutical markets. With significant unmet medical needs in the treatment of Alzheimer’s disease, cognitive disorders, stroke, multiple sclerosis, Parkinson’s disease, and major psychiatric disorders, the demand for innovative CNS therapies should grow rapidly in the years ahead. However, biopharmaceutical companies developing novel CNS products face some unique obstacles: the difficulty of quantifying endpoints for many behavioral disorders; the need new biomarkers and surrogate markets to assess these illnesses; the difficulty of recruiting qualified investigators and treatment-naïve patients; and the specialized requirements for studies involving patients with cognitive disabilities or other impairments.
PAREXEL’s CNS experts provide the experience and resources to help biopharmaceutical companies overcome these obstacles and take advantage of the opportunities in every phase of CNS therapy development. We can meet your need for medical consulting, Phase I in-patient facilities, Proof of Concept studies, large Phase III or Phase IV trials, advanced medical imaging technology, and regulatory strategies – anywhere in the world. In the past five years, PAREXEL has actively participated in more than 540 CNS studies involving more than 114,000 patients across a wide array of disorders. We have more than 100 project managers and 500 CRAs with specific CNS trial experience, plus a database of thousands of qualified CNS investigators across the globe.
Our CNS team is led by board-certified neurologists, psychiatrists, and pharmacologists with years of academic, clinical, and industry experience. These internationally-renowned physicians and scientists apply their insight and knowledge to improve every aspect of your CNS development program, including protocol development, early-stage trials, project management, data management, technology evaluation, site selection, pivotal Phase III trials, statistical analysis, and regulatory submissions. PAREXEL also offers a world-class network of early-phase research units in the US, Europe, and South Africa, with CNS-specific resources that include highly-trained psychiatrists and neurologists, experienced clinicians, specialized in-patient facilities, state-of-the-art testing and monitoring technologies, and an extensive database of healthy volunteers and qualified patients.